nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—STK10—renal vein—vascular cancer	0.221	0.418	CbGeAlD
Vandetanib—FLT4—blood vessel—vascular cancer	0.0306	0.058	CbGeAlD
Vandetanib—RIPK2—blood vessel—vascular cancer	0.0305	0.0577	CbGeAlD
Vandetanib—TEK—blood vessel—vascular cancer	0.0246	0.0466	CbGeAlD
Vandetanib—SRC—blood vessel—vascular cancer	0.0219	0.0414	CbGeAlD
Vandetanib—KDR—blood vessel—vascular cancer	0.0201	0.0381	CbGeAlD
Vandetanib—PDGFRB—blood vessel—vascular cancer	0.0174	0.033	CbGeAlD
Vandetanib—STK35—cardiac atrium—vascular cancer	0.0134	0.0253	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—vascular cancer	0.0123	0.0233	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—vascular cancer	0.0123	0.0233	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—vascular cancer	0.0111	0.021	CbGeAlD
Vandetanib—AXL—cardiac atrium—vascular cancer	0.0109	0.0206	CbGeAlD
Vandetanib—SLK—cardiac atrium—vascular cancer	0.0105	0.0198	CbGeAlD
Vandetanib—FYN—cardiac atrium—vascular cancer	0.0102	0.0193	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—vascular cancer	0.00996	0.0189	CbGeAlD
Vandetanib—TEK—cardiac atrium—vascular cancer	0.00996	0.0189	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—vascular cancer	0.00952	0.018	CbGeAlD
Vandetanib—YES1—cardiac atrium—vascular cancer	0.0092	0.0174	CbGeAlD
Vandetanib—SRC—cardiac atrium—vascular cancer	0.00885	0.0168	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—vascular cancer	0.00814	0.0154	CbGeAlD
Vandetanib—KDR—cardiac atrium—vascular cancer	0.00814	0.0154	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—vascular cancer	0.00705	0.0133	CbGeAlD
Vandetanib—ABL1—cardiac atrium—vascular cancer	0.00628	0.0119	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—vascular cancer	0.00479	0.00906	CbGeAlD
Vandetanib—ERBB3—Signaling by ERBB4—TSC2—vascular cancer	0.00243	0.00516	CbGpPWpGaD
Vandetanib—MAP2K5—Insulin Signaling—TSC2—vascular cancer	0.00242	0.00514	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—WWTR1—vascular cancer	0.0024	0.00509	CbGpPWpGaD
Vandetanib—ERBB3—Downstream signal transduction—TSC2—vascular cancer	0.00232	0.00493	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by FGFR—TSC2—vascular cancer	0.00231	0.0049	CbGpPWpGaD
Vandetanib—ALB—Selenium Micronutrient Network—HBA1—vascular cancer	0.00231	0.0049	CbGpPWpGaD
Vandetanib—PDGFRB—PI-3K cascade—TSC2—vascular cancer	0.00231	0.0049	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by ERBB2—TSC2—vascular cancer	0.0023	0.00488	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—WWTR1—vascular cancer	0.00229	0.00486	CbGpPWpGaD
Vandetanib—ERBB3—DAP12 signaling—TSC2—vascular cancer	0.00229	0.00486	CbGpPWpGaD
Vandetanib—YES1—Signaling by SCF-KIT—TSC2—vascular cancer	0.00227	0.00481	CbGpPWpGaD
Vandetanib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00226	0.00479	CbGpPWpGaD
Vandetanib—PDGFRB—PI3K/AKT activation—TSC2—vascular cancer	0.00226	0.00478	CbGpPWpGaD
Vandetanib—PDGFRB—GAB1 signalosome—TSC2—vascular cancer	0.00224	0.00475	CbGpPWpGaD
Vandetanib—FYN—PI-3K cascade—TSC2—vascular cancer	0.00223	0.00472	CbGpPWpGaD
Vandetanib—VEGFA—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00222	0.00471	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00222	0.00471	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—WWTR1—vascular cancer	0.00219	0.00465	CbGpPWpGaD
Vandetanib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00219	0.00464	CbGpPWpGaD
Vandetanib—BLK—B Cell Activation—TSC2—vascular cancer	0.00217	0.00461	CbGpPWpGaD
Vandetanib—FYN—PI3K/AKT activation—TSC2—vascular cancer	0.00217	0.00461	CbGpPWpGaD
Vandetanib—FYN—GAB1 signalosome—TSC2—vascular cancer	0.00216	0.00457	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by FGFR in disease—TSC2—vascular cancer	0.00215	0.00457	CbGpPWpGaD
Vandetanib—ERBB3—DAP12 interactions—TSC2—vascular cancer	0.00215	0.00457	CbGpPWpGaD
Vandetanib—ERBB3—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00215	0.00457	CbGpPWpGaD
Vandetanib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00214	0.00454	CbGpPWpGaD
Vandetanib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00214	0.00453	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by EGFR—TSC2—vascular cancer	0.00213	0.00453	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00212	0.00449	CbGpPWpGaD
Vandetanib—FYN—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00211	0.00447	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by PDGF—TSC2—vascular cancer	0.00211	0.00447	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—CD34—vascular cancer	0.0021	0.00446	CbGpPWpGaD
Vandetanib—LCK—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.00206	0.00437	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—CD34—vascular cancer	0.00202	0.00429	CbGpPWpGaD
Vandetanib—YES1—Signaling by ERBB2—TSC2—vascular cancer	0.00202	0.00428	CbGpPWpGaD
Vandetanib—ERBB3—B Cell Activation—TSC2—vascular cancer	0.00199	0.00423	CbGpPWpGaD
Vandetanib—MAP2K5—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00198	0.0042	CbGpPWpGaD
Vandetanib—EGFR—PI-3K cascade—TSC2—vascular cancer	0.00192	0.00408	CbGpPWpGaD
Vandetanib—ERBB3—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00191	0.00405	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.00189	0.00401	CbGpPWpGaD
Vandetanib—EGFR—PI3K/AKT activation—TSC2—vascular cancer	0.00188	0.00398	CbGpPWpGaD
Vandetanib—EGFR—GAB1 signalosome—TSC2—vascular cancer	0.00186	0.00395	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—CD34—vascular cancer	0.00186	0.00393	CbGpPWpGaD
Vandetanib—LCK—PI-3K cascade—TSC2—vascular cancer	0.00185	0.00393	CbGpPWpGaD
Vandetanib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00182	0.00386	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—WWTR1—vascular cancer	0.00182	0.00386	CbGpPWpGaD
Vandetanib—LCK—PI3K/AKT activation—TSC2—vascular cancer	0.00181	0.00384	CbGpPWpGaD
Vandetanib—LCK—GAB1 signalosome—TSC2—vascular cancer	0.0018	0.00381	CbGpPWpGaD
Vandetanib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.00175	0.00372	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by SCF-KIT—TSC2—vascular cancer	0.00173	0.00366	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.00171	0.00362	CbGpPWpGaD
Vandetanib—LYN—Signaling by SCF-KIT—TSC2—vascular cancer	0.00169	0.00359	CbGpPWpGaD
Vandetanib—FYN—Signaling by SCF-KIT—TSC2—vascular cancer	0.00166	0.00353	CbGpPWpGaD
Vandetanib—RIPK2—Signaling by NGF—TSC2—vascular cancer	0.00166	0.00353	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00165	0.0035	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—WWTR1—vascular cancer	0.00164	0.00348	CbGpPWpGaD
Vandetanib—FYN—BDNF signaling pathway—TSC2—vascular cancer	0.00164	0.00347	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—CD34—vascular cancer	0.00163	0.00345	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by ERBB4—TSC2—vascular cancer	0.00163	0.00345	CbGpPWpGaD
Vandetanib—ABL1—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00159	0.00338	CbGpPWpGaD
Vandetanib—FYN—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00159	0.00338	CbGpPWpGaD
Vandetanib—SRC—GAB1 signalosome—TSC2—vascular cancer	0.00159	0.00337	CbGpPWpGaD
Vandetanib—FYN—Signaling by ERBB4—TSC2—vascular cancer	0.00157	0.00332	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signal transduction—TSC2—vascular cancer	0.00155	0.00329	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR—TSC2—vascular cancer	0.00155	0.00328	CbGpPWpGaD
Vandetanib—ERBB3—Disease—WWTR1—vascular cancer	0.00154	0.00326	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by ERBB2—TSC2—vascular cancer	0.00154	0.00326	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 signaling—TSC2—vascular cancer	0.00153	0.00325	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling by NGF—TSC2—vascular cancer	0.00152	0.00323	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00151	0.0032	CbGpPWpGaD
Vandetanib—FYN—Downstream signal transduction—TSC2—vascular cancer	0.0015	0.00318	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR—TSC2—vascular cancer	0.00149	0.00316	CbGpPWpGaD
Vandetanib—FYN—Signaling by ERBB2—TSC2—vascular cancer	0.00148	0.00314	CbGpPWpGaD
Vandetanib—FYN—DAP12 signaling—TSC2—vascular cancer	0.00148	0.00313	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by NGF—TSC2—vascular cancer	0.00147	0.00311	CbGpPWpGaD
Vandetanib—FYN—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00145	0.00308	CbGpPWpGaD
Vandetanib—EGFR—Direct p53 effectors—TSC2—vascular cancer	0.00145	0.00307	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR in disease—TSC2—vascular cancer	0.00144	0.00305	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 interactions—TSC2—vascular cancer	0.00144	0.00305	CbGpPWpGaD
Vandetanib—PDGFRB—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00144	0.00305	CbGpPWpGaD
Vandetanib—EGFR—Signaling by SCF-KIT—TSC2—vascular cancer	0.00144	0.00305	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR—TSC2—vascular cancer	0.00143	0.00303	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00141	0.003	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CD34—vascular cancer	0.00141	0.00299	CbGpPWpGaD
Vandetanib—LYN—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00141	0.00299	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by PDGF—TSC2—vascular cancer	0.00141	0.00299	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR in disease—TSC2—vascular cancer	0.00139	0.00294	CbGpPWpGaD
Vandetanib—FYN—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00139	0.00294	CbGpPWpGaD
Vandetanib—FYN—DAP12 interactions—TSC2—vascular cancer	0.00139	0.00294	CbGpPWpGaD
Vandetanib—LCK—Signaling by SCF-KIT—TSC2—vascular cancer	0.00139	0.00294	CbGpPWpGaD
Vandetanib—EGFR—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00138	0.00292	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR—TSC2—vascular cancer	0.00138	0.00292	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00136	0.00289	CbGpPWpGaD
Vandetanib—EGFR—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.00136	0.00289	CbGpPWpGaD
Vandetanib—FYN—Signaling by PDGF—TSC2—vascular cancer	0.00136	0.00288	CbGpPWpGaD
Vandetanib—EGFR—Signaling by ERBB4—TSC2—vascular cancer	0.00135	0.00287	CbGpPWpGaD
Vandetanib—PDGFRB—B Cell Activation—TSC2—vascular cancer	0.00133	0.00283	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.00133	0.00281	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB4—TSC2—vascular cancer	0.00131	0.00277	CbGpPWpGaD
Vandetanib—LYN—B Cell Activation—TSC2—vascular cancer	0.0013	0.00277	CbGpPWpGaD
Vandetanib—EGFR—Downstream signal transduction—TSC2—vascular cancer	0.00129	0.00274	CbGpPWpGaD
Vandetanib—EGFR—Signaling by FGFR—TSC2—vascular cancer	0.00129	0.00273	CbGpPWpGaD
Vandetanib—FYN—B Cell Activation—TSC2—vascular cancer	0.00128	0.00272	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—HBA1—vascular cancer	0.00128	0.00272	CbGpPWpGaD
Vandetanib—EGFR—Signaling by ERBB2—TSC2—vascular cancer	0.00128	0.00272	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD34—vascular cancer	0.00128	0.00271	CbGpPWpGaD
Vandetanib—PDGFRB—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00128	0.0027	CbGpPWpGaD
Vandetanib—EGFR—DAP12 signaling—TSC2—vascular cancer	0.00127	0.0027	CbGpPWpGaD
Vandetanib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00126	0.00266	CbGpPWpGaD
Vandetanib—LCK—Downstream signal transduction—TSC2—vascular cancer	0.00125	0.00264	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD34—vascular cancer	0.00124	0.00263	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR—TSC2—vascular cancer	0.00124	0.00263	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB2—TSC2—vascular cancer	0.00123	0.00262	CbGpPWpGaD
Vandetanib—FYN—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00123	0.00261	CbGpPWpGaD
Vandetanib—LCK—DAP12 signaling—TSC2—vascular cancer	0.00123	0.0026	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD34—vascular cancer	0.00123	0.0026	CbGpPWpGaD
Vandetanib—SRC—Signaling by SCF-KIT—TSC2—vascular cancer	0.00123	0.0026	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD34—vascular cancer	0.00122	0.0026	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—WWTR1—vascular cancer	0.00122	0.00259	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD34—vascular cancer	0.00121	0.00258	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	0.00121	0.00257	CbGpPWpGaD
Vandetanib—SRC—BDNF signaling pathway—TSC2—vascular cancer	0.00121	0.00256	CbGpPWpGaD
Vandetanib—EGFR—Signaling by FGFR in disease—TSC2—vascular cancer	0.0012	0.00254	CbGpPWpGaD
Vandetanib—EGFR—DAP12 interactions—TSC2—vascular cancer	0.0012	0.00254	CbGpPWpGaD
Vandetanib—EGFR—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.0012	0.00254	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD34—vascular cancer	0.0012	0.00254	CbGpPWpGaD
Vandetanib—EGFR—Signaling by EGFR—TSC2—vascular cancer	0.00119	0.00252	CbGpPWpGaD
Vandetanib—EGFR—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00118	0.0025	CbGpPWpGaD
Vandetanib—EGFR—Signaling by PDGF—TSC2—vascular cancer	0.00117	0.00249	CbGpPWpGaD
Vandetanib—LCK—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.00116	0.00245	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR in disease—TSC2—vascular cancer	0.00116	0.00245	CbGpPWpGaD
Vandetanib—LCK—DAP12 interactions—TSC2—vascular cancer	0.00116	0.00245	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR—TSC2—vascular cancer	0.00115	0.00243	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.00114	0.00241	CbGpPWpGaD
Vandetanib—LCK—Signaling by PDGF—TSC2—vascular cancer	0.00113	0.0024	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD34—vascular cancer	0.00113	0.00239	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—WWTR1—vascular cancer	0.00112	0.00237	CbGpPWpGaD
Vandetanib—EGFR—B Cell Activation—TSC2—vascular cancer	0.00111	0.00235	CbGpPWpGaD
Vandetanib—SRC—Downstream signal transduction—TSC2—vascular cancer	0.0011	0.00234	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR—TSC2—vascular cancer	0.0011	0.00233	CbGpPWpGaD
Vandetanib—SRC—Signaling by ERBB2—TSC2—vascular cancer	0.00109	0.00232	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—WWTR1—vascular cancer	0.00109	0.00231	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—WWTR1—vascular cancer	0.00108	0.00228	CbGpPWpGaD
Vandetanib—LCK—B Cell Activation—TSC2—vascular cancer	0.00107	0.00227	CbGpPWpGaD
Vandetanib—EGFR—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00106	0.00225	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—TSC2—vascular cancer	0.00105	0.00223	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD34—vascular cancer	0.00103	0.00219	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—WWTR1—vascular cancer	0.00103	0.00218	CbGpPWpGaD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00102	0.00217	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—TSC2—vascular cancer	0.00102	0.00217	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—TSC2—vascular cancer	0.00101	0.00215	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.001	0.00213	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—TSC2—vascular cancer	0.001	0.00212	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD34—vascular cancer	0.000995	0.00211	CbGpPWpGaD
Vandetanib—FYN—Disease—WWTR1—vascular cancer	0.000991	0.0021	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD34—vascular cancer	0.000988	0.00209	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—TSC2—vascular cancer	0.000981	0.00208	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—WWTR1—vascular cancer	0.000979	0.00208	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—TSC2—vascular cancer	0.000949	0.00201	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—WWTR1—vascular cancer	0.000945	0.00201	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—TSC2—vascular cancer	0.000945	0.00201	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—WWTR1—vascular cancer	0.000928	0.00197	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—HBA1—vascular cancer	0.000918	0.00195	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—TSC2—vascular cancer	0.000911	0.00193	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—TSC2—vascular cancer	0.00091	0.00193	CbGpPWpGaD
Vandetanib—ABCC1—Disease—WWTR1—vascular cancer	0.000908	0.00193	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.000906	0.00192	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD34—vascular cancer	0.000881	0.00187	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—TSC2—vascular cancer	0.000877	0.00186	CbGpPWpGaD
Vandetanib—EGFR—Disease—WWTR1—vascular cancer	0.000856	0.00182	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—TSC2—vascular cancer	0.000837	0.00177	CbGpPWpGaD
Vandetanib—LCK—Disease—WWTR1—vascular cancer	0.000825	0.00175	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—TSC2—vascular cancer	0.000817	0.00173	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—TSC2—vascular cancer	0.000804	0.0017	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—TSC2—vascular cancer	0.000787	0.00167	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TSC2—vascular cancer	0.000767	0.00163	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—WWTR1—vascular cancer	0.000761	0.00161	CbGpPWpGaD
Vandetanib—MKNK1—Disease—TSC2—vascular cancer	0.000759	0.00161	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD34—vascular cancer	0.000752	0.0016	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD34—vascular cancer	0.000737	0.00156	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—TSC2—vascular cancer	0.000735	0.00156	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD34—vascular cancer	0.000733	0.00155	CbGpPWpGaD
Vandetanib—SRC—Disease—WWTR1—vascular cancer	0.000731	0.00155	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD34—vascular cancer	0.000725	0.00154	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—WWTR1—vascular cancer	0.00072	0.00153	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—TSC2—vascular cancer	0.000705	0.0015	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—WWTR1—vascular cancer	0.000705	0.0015	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TSC2—vascular cancer	0.000702	0.00149	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—TSC2—vascular cancer	0.000697	0.00148	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—WWTR1—vascular cancer	0.000694	0.00147	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—WWTR1—vascular cancer	0.000669	0.00142	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TSC2—vascular cancer	0.000642	0.00136	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD34—vascular cancer	0.000626	0.00133	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—TSC2—vascular cancer	0.000611	0.0013	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD34—vascular cancer	0.000604	0.00128	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—WWTR1—vascular cancer	0.0006	0.00127	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—WWTR1—vascular cancer	0.000578	0.00123	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—TSC2—vascular cancer	0.000559	0.00119	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—TSC2—vascular cancer	0.000553	0.00117	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—TSC2—vascular cancer	0.000548	0.00116	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—TSC2—vascular cancer	0.000545	0.00116	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—TSC2—vascular cancer	0.000539	0.00114	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—TSC2—vascular cancer	0.000537	0.00114	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD34—vascular cancer	0.000534	0.00113	CbGpPWpGaD
Vandetanib—BLK—Immune System—TSC2—vascular cancer	0.000532	0.00113	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TSC2—vascular cancer	0.000532	0.00113	CbGpPWpGaD
Vandetanib—FGR—Immune System—TSC2—vascular cancer	0.00053	0.00112	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—TSC2—vascular cancer	0.000526	0.00112	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—TSC2—vascular cancer	0.000518	0.0011	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—WWTR1—vascular cancer	0.000512	0.00108	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—TSC2—vascular cancer	0.000487	0.00103	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—TSC2—vascular cancer	0.000466	0.000988	CbGpPWpGaD
Vandetanib—ERBB3—Disease—TSC2—vascular cancer	0.00045	0.000954	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—TSC2—vascular cancer	0.000449	0.000952	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—TSC2—vascular cancer	0.000447	0.000949	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—TSC2—vascular cancer	0.000431	0.000914	CbGpPWpGaD
Vandetanib—YES1—Immune System—TSC2—vascular cancer	0.000428	0.000907	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—HBA1—vascular cancer	0.000426	0.000903	CbGpPWpGaD
Vandetanib—ALB—Metabolism—WWTR1—vascular cancer	0.000413	0.000876	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—TSC2—vascular cancer	0.000397	0.000843	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—TSC2—vascular cancer	0.000382	0.000809	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—HBA1—vascular cancer	0.000375	0.000795	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TSC2—vascular cancer	0.000357	0.000758	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TSC2—vascular cancer	0.000327	0.000693	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—TSC2—vascular cancer	0.000326	0.000691	CbGpPWpGaD
Vandetanib—LYN—Immune System—TSC2—vascular cancer	0.000319	0.000677	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TSC2—vascular cancer	0.000319	0.000676	CbGpPWpGaD
Vandetanib—ABL1—Immune System—TSC2—vascular cancer	0.000318	0.000673	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TSC2—vascular cancer	0.000315	0.000668	CbGpPWpGaD
Vandetanib—FYN—Immune System—TSC2—vascular cancer	0.000314	0.000666	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TSC2—vascular cancer	0.000301	0.000638	CbGpPWpGaD
Vandetanib—FYN—Disease—TSC2—vascular cancer	0.00029	0.000615	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TSC2—vascular cancer	0.000286	0.000607	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TSC2—vascular cancer	0.000277	0.000587	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TSC2—vascular cancer	0.000271	0.000575	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TSC2—vascular cancer	0.000266	0.000564	CbGpPWpGaD
Vandetanib—LCK—Immune System—TSC2—vascular cancer	0.000261	0.000555	CbGpPWpGaD
Vandetanib—EGFR—Disease—TSC2—vascular cancer	0.000251	0.000531	CbGpPWpGaD
Vandetanib—LCK—Disease—TSC2—vascular cancer	0.000241	0.000512	CbGpPWpGaD
Vandetanib—SRC—Immune System—TSC2—vascular cancer	0.000231	0.000491	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HBA1—vascular cancer	0.000231	0.00049	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—WWTR1—vascular cancer	0.000223	0.000473	CbGpPWpGaD
Vandetanib—SRC—Disease—TSC2—vascular cancer	0.000214	0.000453	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TSC2—vascular cancer	0.000211	0.000447	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TSC2—vascular cancer	0.000206	0.000437	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TSC2—vascular cancer	0.000203	0.000431	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TSC2—vascular cancer	0.000175	0.000372	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TSC2—vascular cancer	0.000169	0.000359	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSC2—vascular cancer	0.00015	0.000317	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HBA1—vascular cancer	0.000125	0.000265	CbGpPWpGaD
